From Genome Exploration to Drug Development

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-06-02-2003, Volume 27, Issue 6

FDA's plan to establish pharmacogenomic policies spurs concerns among manufacturers, particularly in regard to how the policies will affect new-drug testing and approval.

Related Content:

Regulatory WatchPharmaceutical Technology-06-02-2003
Responding to the Increased Use of Generative AI
Signing Off from Washington
Industry Challenges Medicare Price Negotiation Scheme